{"id":"remi-0-2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This dual-action mechanism allows for increased levels of these neurotransmitters in the brain, which can help improve mood and reduce symptoms of depression. By inhibiting the reuptake of serotonin and norepinephrine, Remi 0.2 can help increase the amount of time these neurotransmitters are available to bind to their receptors, leading to improved mood and reduced symptoms of depression.","oneSentence":"Remi 0.2 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:37.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT02799589","phase":"PHASE4","title":"Remifentanil-dexmedetomidine Anesthesia With a Caudal for Elective Surgery. (Remi-dex)","status":"WITHDRAWN","sponsor":"Mofya Diallo","startDate":"2016-07","conditions":"Anesthesia","enrollment":""},{"nctId":"NCT02763098","phase":"PHASE4","title":"Remifentanil on Hemodynamic Response to Anesthesia Induction","status":"COMPLETED","sponsor":"Dokuz Eylul University","startDate":"2012-01","conditions":"Anesthesia","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["remifentanil, Ultiva, Glaxo Wellcome, Marly-le-Roi, France"],"phase":"marketed","status":"active","brandName":"Remi 0.2","genericName":"Remi 0.2","companyName":"Dokuz Eylul University","companyId":"dokuz-eylul-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Remi 0.2 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}